Steven Cohen Roivant Sciences Ltd. Transaction History

Point72 Asset Management, L.P.

$44.6 Billion
Q2 2025

A detailed history of Steven Cohen (Point72 Asset Management, L.P.) transactions in Roivant Sciences Ltd. stock. As of the latest transaction made, Point72 Asset Management, L.P. holds 2,951,132 shares of ROIV stock, worth $47.7 Million. This represents 0.07% of its overall portfolio holdings.

Number of Shares

2,951,132

Previous 614,315 380.39%

Holding current value

$47.7 Million

Previous $6.2 Million 436.61%

% of portfolio

0.07%

Previous 0.02%

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2025 Aug 14, 2025	BUY	$9.08 - $11.62 $21.2 Million - $27.2 Million	2,336,817 Added 380.39%	2,951,132 $33.3 Million
Q1 2025 May 15, 2025	BUY	$10.09 - $12.08 $6.2 Million - $7.42 Million	614,315 New	614,315 $6.2 Million
Q2 2024 Aug 14, 2024	BUY	$10.36 - $11.74 $1.92 Million - $2.17 Million	185,226 Added 40.1%	647,126 $6.84 Million
Q1 2024 May 15, 2024	BUY	$9.87 - $11.8 $278,334 - $332,760	28,200 Added 6.5%	461,900 $4.87 Million
Q4 2023 Feb 14, 2024	SELL	$8.38 - $11.58 $19 Million - $26.3 Million	-2,272,700 Reduced 83.98%	433,700 $4.87 Million
Q3 2023 Nov 14, 2023	BUY	$9.76 - $13.19 $26.4 Million - $35.7 Million	2,706,400 New	2,706,400 $31.6 Million
Q1 2023 May 15, 2023	SELL	$6.92 - $9.98 $3.99 Million - $5.76 Million	-576,800 Closed	0 $0
Q4 2022 Feb 14, 2023	BUY	$3.36 - $7.99 $1.94 Million - $4.61 Million	576,800 New	576,800 $4.61 Million
Q2 2022 Aug 15, 2022	BUY	$2.81 - $4.84 $2.46 Million - $4.24 Million	876,996 New	876,996 $3.57 Million

Others Institutions Holding ROIV

# of Institutions

363

Shares Held

456M

Call Options Held

8.36M

Put Options Held

760K

View Full List

About Roivant Sciences Ltd.

Ticker ROIV
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 704,382,976
Market Cap $11.4B
Description
Roivant Sciences Ltd., a biopharmaceutical and healthcare technology company that researches and develops medicines. The company develops product candidates for the treatment of various therapeutics, including solid tumors, sickle cell diseases, hypophosphatasia, oncologic malignancies, psoriasis, atopic dermatitis, vitiligo, hyperhidrosis, acne...

More about ROIV

Track Steven Cohen's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Point72 Asset Management, L.P., based on Form 13F filings with the SEC.

News

Stay updated on Point72 Asset Management, L.P. and Steven Cohen with notifications on news.

Account